1333163-20-4

Basic information

• Product Name: (E)-N-(4-(3-chlorophenylamino)quinazolin-6-yl)-3-(naphthalen-4-yl)acrylamide
• Synonyms: (E)-N-(4-(3-chlorophenylamino)quinazolin-6-yl)-3-(naphthalen-4-yl)acrylamide
• CAS NO: 1333163-20-4
• Molecular Weight: 450.927
• Mol File: 1333163-20-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (E)-N-(4-(3-chlorophenylamino)quinazolin-6-yl)-3-(naphthalen-4-yl)acrylamide(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-N-(4-(3-chlorophenylamino)quinazolin-6-yl)-3-(naphthalen-4-yl)acrylamide(1333163-20-4)
• EPA Substance Registry System: (E)-N-(4-(3-chlorophenylamino)quinazolin-6-yl)-3-(naphthalen-4-yl)acrylamide(1333163-20-4)

Safety Data

• Hazardous Substances Data: 1333163-20-4(Hazardous Substances Data)

Upstream product

• 153436-72-7 4-<(3-chlorophenyl)amino>-6-nitroquinazoline 
• 153436-71-6 6-amino-4-[(3-chlorophenyl)amino]quinazoline 
• 120681-10-9 (E)‐3‐(naphthalen‐1‐yl)acryloyl chloride 
• 66-77-3 1-naphthaldehyde 
• 13026-12-5 (E)-3-(naphthalen-1-yl)acrylic acid 
• 39263-34-8 N′-(2-cyano-4-nitrophenyl)-N,N-dimethylformimidamide 
• 17420-30-3 5-nitroanthranilonitrile 

Relevant articles and documents

The combination of 4-anilinoquinazoline and cinnamic acid: A novel mode of binding to the epidermal growth factor receptor tyrosine kinase

A novel type of cinnamic acid quinazoline amide derivatives (20-42), which designed the combination between quinazoline as the backbone and various substituted cinnamic acid as the side chain, have been synthesized and their biological activities were evaluated within cytotoxicity assay firstly and then potent EGFR inhibitory activity. Compound 42 demonstrated the most potent inhibitory activity (IC50 = 0.94 μM for EGFR), which could be optimized as a potential EGFR inhibitor in the further study. Docking simulation was performed to position compound 42 into the EGFR active site to determine the probable binding model. Analysis of the binding conformation of 42 in active site displayed compound 42 was stabilized by hydrogen bonding interactions with Lys822, which was different from other derivatives. In the further study, Compounds 43 and 44 had been synthesized and their biological activities were also evaluated, which were the same as that we expected. Compound 43 has demonstrated significant EGFR (IC50 = 0.12 μM) and tumor growth inhibitory activity as a potential anticancer agent.